ClinicalTrials.gg
CompletedNCT04778176SCOLUpdated Aug 10, 2022

Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients

A Phase 2 interventional study of continuous oral delivery of levodopa/carbidopa in Parkinson's Disease, sponsored by SynAgile Corporation. Completed at 5 sites in 3 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by SynAgile Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 347 studies in Parkinson Disease with a site in Italy — 89 open to participants now, 107 under way, 4 of them phase 3. Parkinson Disease · Italy.

Enrollment
232nd of 244
17 · median 82
Started
2021
with 30 others
Phase 2
33 of 347
2 open now
Registered
192nd of 347
by date

Among the 347 studies in Parkinson Disease with a site in Italy, this one is the 232nd largest by enrollment of the 244 interventional ones that give a count, is one of 31 that started in 2021, is one of 33 in phase 2, and was the 192nd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

89 of the 347 studies in Parkinson Disease with a site in Italy are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 347 studies in Parkinson Disease with a site in Italy, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether the DopaFuse System can reduce the fluctuation of plasma levodopa levels compared to participants' standard intermittent doses of oral LD/CD tablets (background treatment). It will also assess whether the system is safe, well tolerated, and can relieve motor symptoms.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Parkinson's Disease consistent with UK Brain Bank Criteria
  2. Age at least 30 years old at time of consent
  3. Male and Female participants (Women of (WOCB) are eligible for participation if they are not pregnant or breastfeeding and agree to follow the guidance in Appendix 3 during the treatment period and for at least 30 days after the last dose of study treatment)
  4. Suitable for oral retainer wear
  5. A good response to Levodopa, as assessed by the Investigator
  6. At least 2 hours of wearing OFF time per day, as reported by the participant
  7. Predictable early morning OFF periods, in the judgement of the participant and the Investigator
  8. Taking 400-1,200 mg of LD/CD per day in at least 4 doses, with stable dosing for the last 28 days prior to screening.
  9. A modified Hoehn and Yahr of ≤ 3 in the ON state at screening
  10. A stable regimen of anti-PD medications for the last 28 days prior to Screening
  11. A (MMSE) Score ≥26
  12. Capable of giving signed
  13. Approved for entry into the study by the Enrollment Authorization Committee (EAC)

Exclusion criteria

Exclusion Criteria:

  1. Atypical or secondary Parkinson's Disease
  2. Severe Dyskinesia that might interfere with study performance in the judgement of Investigator
  3. dysphagia or sialorrhea that might interfere with administration of study intervention in the judgement of the Investigator
  4. Use of extended release levodopa within 28 days prior to screening
  5. Any clinically significant medical, surgical, or psychiatric condition; laboratory value or result which, in the opinion of the Investigator, makes the participant unsuitable for study entry or potentially unable to complete all aspects of the study.
  6. Presence of clinically significant orthostatic hypotension at screening, in the opinion of Investigator or the EAC
  7. Suicidal ideation within 1 year prior to the Screening Visit as evidenced by answering "yes" to Questions 4 or 5 on the suicidal ideation portion of the Columbia Suicide Severity Rating Scale (C-SSRS) or attempted suicide within the last 5 years.
  8. History of psychosis or hallucinations in the past six months
  9. Any in the past 5 years (excluding basal cell carcinoma of the skin or cervical carcinoma in situ that have been successfully treated.)
  10. Current or previous diagnosis of malignant melanoma or the presence of any suspicious skin lesion based on physical exam findings
  11. Unable to give blood required for the study
  12. History of allergic reaction to plastics
  13. LD infusion therapy (i.e. Duodopa); current or previous continuous apomorphine infusion treatment.
  14. Participation in any other clinical trial \<30 days prior to screening visit.
  15. Presence of two third molars ("wisdom teeth") on the upper dentition
  16. Participants who, for any reason, are judged by the Investigator or the EAC to be inappropriate for this study, including participants who are unable to communicate or cooperate with the Investigator or who have/had a clinically significant illness or abnormal physical examination that may compromise safety of the participant during the trial or affect ability of the participant to adhere to study procedures.
  17. Participants taking non-selective monoamine oxidase (MAO) inhibitors
  18. Participants with known to the active ingredients (levodopa, carbidopa) or (Benzoic Acid, Disodium Edetate, Medium Chain Triglycerides, Poloxamer 188) of the drug paste
  19. Participants with narrow-angle glaucoma
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    DopaFuse Delivery System 50mg LD/hr or 68mg LD/hr flow rate

    Either 50mg/13mg LD/CD per hour or 68mg/17mg LD/CD per hour flow rate based upon Subject's standard levodopa (LD) dose. Subjects will routinely wear each container for approximately 5 hours (3 containers per day).

    Combination Product: continuous oral delivery of levodopa/carbidopa

Interventions

  • Combination productcontinuous oral delivery of levodopa/carbidopa

    The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.

06

What researchers measure

Primary outcomes

  1. Variability in plasma concentration of levodopa as assessed with the Levodopa Fluctuation Index (Cmax-Cmin)/Caverage)

    Comparing Day 2 to Day 1 in steady state (4-12 hours). Fluctuation index will also be calculated by the hour.

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2.

  2. Treatment Emergent Adverse Events

    Time frame: Screening to Day 29

  3. Serious Adverse Events

    Time frame: Screening to Day 29

  4. Treatment Emergent Adverse Events leading to discontinuation

    Time frame: Screening to Day 29

  5. Percent of participants that complete study

    Time frame: Screening to Day 29

  6. Difference in OFF time between Days 1 and 15, based on in-person investigator ratings

    Investigator-rated assessment of motor state (ON or OFF) pre-dose and every 30 minutes for 12 hours.

    Time frame: Day 1 compared to Day 15

Secondary outcomes

  1. Coefficient of variation (CV) for plasma levodopa.

    This will be calculated between 4 and 12 hours on Days 1 and 2 comparing DopaFuse and oral levodopa tablets.

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2.

  2. Variability in plasma concentration of levodopa as assessed with the Levodopa Fluctuation Index (Cmax-Cmin)/Caverage).

    Comparing Day 3 to Day 1, as well as Day 2 (0-12 hours) to Day 1. Fluctuation index will also be calculated by the hour.

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2. Pre-dose and at 30 minute intervals for two hours, and at one-hour intervals for the remainder of the 12 hours on Day 3.

  3. Levodopa and Carbidopa peak plasma concentration (Cmax)

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2. Pre-dose and at 30 minute intervals for two hours, and at one-hour intervals for the remainder of the 12 hours on Day 3.

  4. Variability in plasma levodopa comparing Dopafuse and oral levodopa tablets based on fluctuation index and CV in participants who are H. pylori negative/positive

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2. Pre-dose and at 30 minute intervals for two hours, and at one-hour intervals for the remainder of the 12 hours on Day 3.

  5. Questionnaire for Impulse Control Disorders in Parkinson's Disease Rating Scale (QUIP-RS)

    Time frame: Screening to Day 29

  6. Columbia - Suicide Severity Rating Scale (C-SSRS)

    Time frame: Screening to Day 29

  7. Difference in OFF Time between Day 1 and Day 3

    Investigator-rated assessment of motor state (ON or OFF) pre-dose and every 30 minutes for 12 hours.

    Time frame: Day 1 and Day 3

  8. Difference in ON Time without troublesome dyskinesia between Days 1, 3 and 15

    Investigator-rated assessment of motor state (ON or OFF) pre-dose and every 30 minutes for 12 hours.

    Time frame: Days 1, 3, and 15

  9. Difference in ON Time with troublesome (severe) dyskinesia between Days 1, 3 and 15

    Investigator-rated assessment of motor state (ON or OFF) pre-dose and every 30 minutes for 12 hours.

    Time frame: Days 1, 3 and 15

  10. Change in Unified Parkinson's Disease Rating Scale Part III at 6 hours after morning dose between Days 1, 3 and 15

    Time frame: Days 1, 3 and 15

  11. Levodopa and Carbidopa time to maximum plasma concentration (Tmax)

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2. Pre-dose and at 30 minute intervals for two hours, and at one-hour intervals for the remainder of the 12 hours on Day 3.

  12. Levodopa and Carbidopa area under the plasma concentration versus time curve (AUC)

    Time frame: pre-dose and every 30 minutes for 12 hours on Days 1 and 2. Pre-dose and at 30 minute intervals for two hours, and at one-hour intervals for the remainder of the 12 hours on Day 3.

Other outcomes

  1. A comparison of the subgroups who are H. pylori positive and negative will be performed as an exploratory analysis.

    Time frame: Screening to Day 15

07

Study locations

5 sites
  • San Raffaele Cassino
    Cassino, 03043, Italy
  • Centro Parkinson, Policlinico Tor Vergata
    Rome, 00133, Italy
  • IRCCS San Raffaele Pisana
    Rome, 00163, Italy
  • Centre Hospitalier de Luxembourg
    Luxembourg, Luxembourg
  • Neuroscience Centre (CINAC)
    Móstoles, 28938, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jul 2022, 13 months.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 13 months is below that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Mar 2, 2021
StartActual
Jun 16, 2021
Primary completionActual
Jul 21, 2022
CompletionActual
Aug 2, 2022
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04778176
Lead sponsor
SynAgile Corporation
Collaborators
Clintrex Research Corporation, TFS Trial Form Support, Clinical Data Science GmbH
Responsible party
Sponsor
First posted
Mar 2, 2021
Start date
Jun 16, 2021
Primary completion
Jul 21, 2022
Completion
Aug 2, 2022
Last update
Aug 10, 2022

Study contacts

Ephraim Heller, MBA
study chair · SynAgile Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion